Published in Graefes Arch Clin Exp Ophthalmol on May 05, 2009
Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol (2012) 2.14
Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol (2012) 1.21
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf (2012) 1.08
Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. J Ophthalmol (2011) 1.02
Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol (2013) 0.98
Topical ranibizumab as a treatment of corneal neovascularization. Cornea (2013) 0.89
The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats. Graefes Arch Clin Exp Ophthalmol (2010) 0.87
Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells. Mol Vis (2011) 0.83
Emerging techniques to treat corneal neovascularisation. Eye (Lond) (2011) 0.82
Subconjunctival bevacizumab in the impending recurrent pterygia. Int Ophthalmol (2013) 0.80
Emerging roles for antiangiogenesis factors in management of ocular disease. Clin Ophthalmol (2013) 0.80
Inhibitory effects of topical cyclosporine A 0.05% on immune-mediated corneal neovascularization in rabbits. Graefes Arch Clin Exp Ophthalmol (2013) 0.79
Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study. J Ocul Biol Dis Infor (2013) 0.77
Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization. Invest Ophthalmol Vis Sci (2014) 0.77
Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia. J Ocul Pharmacol Ther (2015) 0.76
Clinical use of Bevacizumab in treating refractory glaucoma. J Med Life (2015) 0.76
[Antiangiogenic therapy at the ocular surface: when, what and why?]. Ophthalmologe (2011) 0.76
[Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction]. Ophthalmologe (2011) 0.76
Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model. Int J Mol Sci (2013) 0.76
Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab. Graefes Arch Clin Exp Ophthalmol (2014) 0.76
Regression of aggressive corneal vascularization after photodynamic therapy, subconjunctival Avastin injections and topical cyclosporin-A 1% drops: A case report. Saudi J Ophthalmol (2010) 0.75
Clinical Findings, Follow-up and Treatment Results in Patients with Ocular Rosacea. Turk J Ophthalmol (2016) 0.75
Safety of Cultivated Limbal Epithelial Stem Cell Transplantation for Human Corneal Regeneration. Stem Cells Int (2017) 0.75
Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats. J Res Med Sci (2017) 0.75
Genome-wide expression differences in anti-Vegf and dexamethasone treatment of inflammatory angiogenesis in the rat cornea. Sci Rep (2017) 0.75
Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. Saudi J Ophthalmol (2017) 0.75
Update on the Management of High-Risk Penetrating Keratoplasty. Curr Ophthalmol Rep (2017) 0.75
Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy. J Curr Ophthalmol (2016) 0.75
Angiogenesis in cancer and other diseases. Nature (2000) 28.28
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01
Corneal neovascularization. Curr Opin Ophthalmol (2001) 3.22
Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci (2004) 2.27
The effect of topical bevacizumab on corneal neovascularization. Ophthalmology (2008) 2.26
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci (2007) 2.05
Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res (2008) 1.85
Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A (2006) 1.81
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci (2000) 1.71
New roles for VEGF in nervous tissue--beyond blood vessels. Exp Neurol (2004) 1.64
The plasminogen activator system: biology and regulation. Cell Mol Life Sci (1999) 1.52
Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol (2008) 1.27
Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost (1999) 1.19
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (2007) 1.15
Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol (2003) 1.12
Safety profile of bevacizumab on cultured human corneal cells. Cornea (2007) 1.12
Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist (2004) 0.97
[Inhibition of angiogenesis in the anterior chamber of the eye]. Ophthalmologe (2007) 0.94
Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci (1990) 0.88
Corneal nerves: structure, contents and function. Exp Eye Res (2003) 4.21
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 3.77
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med (2004) 2.64
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci (2007) 2.05
Epithelial-Mesenchymal Transition (EMT)-Related Cytokines in the Aqueous Humor of Phakic and Pseudophakic Fuchs' Dystrophy Eyes. Invest Ophthalmol Vis Sci (2015) 2.04
Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol (2009) 1.97
Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci (2003) 1.93
Optimizing descemet membrane endothelial keratoplasty using intraoperative optical coherence tomography. JAMA Ophthalmol (2013) 1.82
Descemet membrane endothelial keratoplasty versus descemet stripping automated endothelial keratoplasty. Am J Ophthalmol (2012) 1.68
GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology (2009) 1.67
Pressure-induced interlamellar stromal keratitis after laser in situ keratomileusis. Cornea (2011) 1.66
Histologic analysis of descemet stripping in posterior lamellar keratoplasty. Arch Ophthalmol (2008) 1.52
Reproducibility of graft preparations in Descemet's membrane endothelial keratoplasty. Ophthalmology (2013) 1.51
Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology (2010) 1.46
Surgery-related factors influencing corneal neovascularization after low-risk keratoplasty. Am J Ophthalmol (2006) 1.41
A stepwise approach to donor preparation and insertion increases safety and outcome of Descemet membrane endothelial keratoplasty. Cornea (2011) 1.40
The Pathogenesis of floppy eyelid syndrome: involvement of matrix metalloproteinases in elastic fiber degradation. Ophthalmology (2005) 1.36
Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol (2002) 1.33
Split cornea transplantation for 2 recipients: a new strategy to reduce corneal tissue cost and shortage. Ophthalmology (2010) 1.29
Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol (2007) 1.29
Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol (2008) 1.27
Descemet membrane endothelial keratoplasty: the taming of the shrew. JAMA Ophthalmol (2013) 1.24
Descemet stripping endothelial keratoplasty--rapid recovery of visual acuity. Dtsch Arztebl Int (2013) 1.24
Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res (2013) 1.22
Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci (2005) 1.22
Bacterial keratitis early after corneal crosslinking with riboflavin and ultraviolet-A. J Cataract Refract Surg (2009) 1.21
Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology (2010) 1.21
Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol (2007) 1.20
Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol (2007) 1.16
Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol (2007) 1.15
Corneal higher-order aberrations after Descemet's membrane endothelial keratoplasty. Ophthalmology (2011) 1.14
Ciliary body lymphangiogenesis. Ophthalmology (2013) 1.11
Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med (2011) 1.10
Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea (2012) 1.10
Optimising deep anterior lamellar keratoplasty (DALK) using intraoperative online optical coherence tomography (iOCT). Br J Ophthalmol (2014) 1.09
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp Eye Res (2004) 1.08
Pentacam-based big bubble deep anterior lamellar keratoplasty in patients with keratoconus. Cornea (2012) 1.07
Split cornea transplantation for 2 recipients - review of the first 100 consecutive patients. Am J Ophthalmol (2011) 1.07
Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci (2009) 1.04
Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci (2009) 1.02
Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea (2008) 1.02
Split cornea transplantation: relationship between storage time of split donor tissue and outcome. Ophthalmology (2013) 1.01
Profiling of WDR36 missense variants in German patients with glaucoma. Invest Ophthalmol Vis Sci (2008) 1.00
Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol (2011) 1.00
Corneal (lymph)angiogenesis--from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol (2008) 1.00
The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci (2008) 0.98
Tear film osmolarity measurements in dry eye disease using electrical impedance technology. Cornea (2011) 0.98
Adhesion structures of amniotic membranes integrated into human corneas. Invest Ophthalmol Vis Sci (2006) 0.97
Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea (2012) 0.96
Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS One (2011) 0.96
Descemet membrane endothelial keratoplasty combined with phacoemulsification and intraocular lens implantation: advanced triple procedure. Am J Ophthalmol (2012) 0.96
Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology (2011) 0.96
Ocular diseases in metastatic cutaneous melanoma: review of 108 consecutive patients in two German tertiary centers. Graefes Arch Clin Exp Ophthalmol (2014) 0.95
Improving glaucoma diagnosis by the combination of perimetry and HRT measurements. J Glaucoma (2006) 0.95
Donor tissue culture conditions and outcome after descemet membrane endothelial keratoplasty. Am J Ophthalmol (2011) 0.94
Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol (2010) 0.93
A new surgical triple procedure in pseudoexfoliation glaucoma using cataract surgery, Trabectome, and trabecular aspiration. Graefes Arch Clin Exp Ophthalmol (2014) 0.93
Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology (2009) 0.92
Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J Immunol (2010) 0.92
Intraoperative Optical Coherence Tomography Enables Noncontact Imaging During Canaloplasty. J Glaucoma (2016) 0.92
Expression of bone morphogenetic proteins (BMPs), their receptors, and activins in normal and scarred conjunctiva: role of BMP-6 and activin-A in conjunctival scarring? Exp Eye Res (2006) 0.92
Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci (2008) 0.91
Microbubble incision as a new rescue technique for big-bubble deep anterior lamellar keratoplasty with failed bubble formation. Cornea (2013) 0.91
Rebound, applanation, and dynamic contour tonometry in pathologic corneas. Cornea (2013) 0.91
Histopathological changes after deep anterior lamellar keratoplasty using the 'big-bubble technique'. Acta Ophthalmol (2011) 0.89
Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. Blood (2012) 0.89
Long-term results of phototherapeutic keratectomy for corneal map-dot-fingerprint dystrophy (Cogan-Guerry). Cornea (2006) 0.89
Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci (2011) 0.88
Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. J Immunol (2013) 0.88
A method to confirm correct orientation of descemet membrane during descemet membrane endothelial keratoplasty. Am J Ophthalmol (2010) 0.87
The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages. Invest Ophthalmol Vis Sci (2012) 0.86
Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy (CIDP). J Peripher Nerv Syst (2014) 0.85
Myofibroblast metaplasia after descemet membrane endothelial keratoplasty. Am J Ophthalmol (2011) 0.85
Corneal graft alterations after Descemet stripping: implications for split cornea transplantation. JAMA Ophthalmol (2013) 0.84
Recurrent interface abscess secondary to Acanthamoeba keratitis treated by deep anterior lamellar keratoplasty. Int J Ophthalmol (2012) 0.84
Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye. J Ocul Pharmacol Ther (2012) 0.84
"PISK-itis" or "PISK-opathy"? Cornea (2012) 0.84
Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci (2014) 0.84
Corneal nerve alterations after Descemet membrane endothelial keratoplasty: an in vivo confocal microscopy study. Cornea (2014) 0.84
Spectrum of Uveitis in A German Tertiary Center: Review of 474 Consecutive Patients. Ocul Immunol Inflamm (2015) 0.84
Characterization of the cleavage plane in DESCemet's membrane endothelial keratoplasty. Ophthalmology (2011) 0.82
Atopic dermatitis as a risk factor for graft rejection following normal-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol (2008) 0.82
Topical Ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol (2012) 0.82
The association between corneal neovascularization and visual acuity: a systematic review. Acta Ophthalmol (2011) 0.82
Lymphatic vessels in the development of tissue and organ rejection. Adv Anat Embryol Cell Biol (2014) 0.81
Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. 2004. Ocul Immunol Inflamm (2007) 0.81
Endothelial cell microRNA expression in human late-onset Fuchs' dystrophy. Invest Ophthalmol Vis Sci (2014) 0.81
Morphometric analysis of postoperative corneal neovascularization after high-risk keratoplasty: herpetic versus non-herpetic disease. Graefes Arch Clin Exp Ophthalmol (2012) 0.81